



1641

#34

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

RECEIVED

Application Serial Number: 08/466,381A  
Source: 1600  
Date Processed by STIC: 8/6/2002

AUG 12 2002

TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name,  
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,  
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,  
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

RECEIVED



AUG 12 2002

TECH CENTER 1600/2900

1600

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/08/466,381A

DATE: 08/06/2002

TIME: 17:12:26

Input Set : A:\EP.txt

Output Set: N:\CRF3\08062002\H466381A.raw

Does Not Comply  
Corrected Diskette Needed

1 <110> APPLICANT: Israeli, Ron S. Heston,  
 W--> 2 <120> TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN<130>  
 W--> 3 <140> CURRENT APPLICATION NUMBER: US 08/466,381<141> 1995-06-06<150> USA  
 W--> 0 <130> FILE REFERENCE:  
 C--> 4 <141> CURRENT FILING DATE: 1995-06-06  
 W--> 4 <151> PRIOR FILING DATE: 1995-03-17<160> 38 <170> PatentIn version 3.1<210> 1<211>

## ERRORRED SEQUENCES

5 &lt;212&gt; TYPE: DNA&lt;213&gt; Human&lt;400&gt; 1

W--&gt; 6 &lt;210&gt; SEQ ID NO:

W--&gt; 6 &lt;211&gt; LENGTH:

W--&gt; 6 &lt;213&gt; ORGANISM:

E--&gt; 6 &lt;400&gt; SEQUENCE:

6	ctaaaaggg	gccggattc	tttctctgg	aggcagatgt	tgcctctctc	tctcgctcgg	60
8	attgttcag	tgcactctag	aaacactgt	gtggtgaga	aactggaccc	caggtctgga	120
10	gcgaattcca	gcctgcaggg	ctgataagcg	aggcattagt	gagattgaga	gagactttac	180
12	ccggccgtgg	tggttggagg	gcgcgcagta	gagcagcagc	acaggcgcgg	gtccccggag	240
14	ccggctctg	ctcgccgca	gatgtggaat	ctccttcacg	aaaccgactc	ggctgtggcc	300
16	accgcgcgcc	gcccgcgtg	gctgtgcgt	ggggcgctgg	tgctggcggg	tggcttcctt	360
18	ctcctcggt	tcctctcgg	gtggttata	aaatcctcca	atgaagctac	taacattact	420
20	ccaaagcata	atatgaaagc	atttttggat	gaattgaaag	ctgagaacat	caagaagttc	480
22	ttatataatt	ttacacagat	accacattta	gcaggaacag	aacaaaactt	tcagcttgca	540
24	aagcaaattc	aatcccagt	gaaagaattt	ggcctggatt	ctgttgagct	agcacattat	600
26	gatgtctgt	tgtcctaccc	aaataagact	catcccaact	acatctcaat	aattaatgaa	660
28	gatggaaatg	agatttcaa	cacatcatta	tttgaaccac	ctcctccagg	atatgaaaat	720
30	gttcggata	ttgttaccacc	tttcagtgt	ttctctccctc	aaggaaatgcc	agagggcgat	780
32	ctagtgtatg	ttaactatgc	acgaactgaa	gacttcttta	aatttggaaacg	ggacatgaaa	840
34	atcaatttgt	ctggggaaat	tgttattgtcc	agatatggaa	aagttttcag	aggaaataaag	900
36	gttaaaaaatg	cccagctggc	aggggcca	ggagtcat	tctactccga	ccctgctgac	960
38	tacccatgtc	ctggggtgaa	gtcctatcca	gatggttgga	atcttcttgg	aggtgggtgc	1020
40	cagcgtggaa	atatcctaaa	tctgaatgg	gcaggagacc	ctctcacacc	aggttaccca	1080
42	gcaaatgaat	atgcttatag	gctgtggatt	gcagaggtg	ttggcttcc	aagtattcc	1140
44	gttcatccaa	ttggatacta	tgtatgcacag	aagctccat	aaaaaatggg	tggctcagca	1200
46	ccaccagata	gcagctggag	aggaagtctc	aaagtccct	acaatgttgg	acctggctt	1260
48	actggaaact	tttctacaca	aaaagtcaag	atgcacatcc	actctaccaa	tgaagtgaca	1320
50	agaatttaca	atgtgatagg	tactctcaga	ggagca	aaccagacag	atatgtcatt	1380
52	ctggggagg	accgggactc	atgggtgtt	ggtggattt	accctcagag	tggagcagct	1440
54	gttggatgt	aaattgtgag	gagcttgg	acactgaaa	aggaagggtg	gagacctaga	1500
56	agaacaattt	tgtttcaag	ctgggatgca	gaagaattt	gtcttcttgg	ttctactgag	1560
58	tggcagagg	agaattcaag	actccttcaa	gagcgtggcg	tggcttat	taatgtcag	1620
60	tcatctatag	aaggaaacta	cactctgaga	gttgattgt	caccgctgat	gtacagctt	1680

*sample of submitted file - global  
format  
errors*

*Please  
contact  
Robert Wax*

*703-306-4119*

*or*

*703-308-4216*

*for  
assistance*



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER

35

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Gucker whose telephone number is (703) 308-6571. The examiner can normally be reached on Monday to Friday from 0930 to 1800. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623. The fax phone number for this Group is currently (703) 308-4242, but Applicant should confirm this by phoning the Examiner before faxing.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

*SG*

Stephen Gucker

October 17, 2002

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:
- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**